

Onconova Therapeutics, Inc.
Form 3
July 24, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â GROOPMAN JEROME
(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
07/24/2013

3. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc. [ONTX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director 10% Owner
 Officer Other
(give title below) (specify below)

C/O ONCONOVA
THERAPEUTICS, INC.,Â 375
PHEASANT RUN

(Street)

NEWTOWN,Â PAÂ 18940

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Date Exercisable

Expiration Date

Title

Amount or Number of

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

				Shares		or Indirect (1) (Instr. 5)	
Stock Option (right to purchase)	02/01/2012	02/01/2022	Common Stock	375	\$ 6.13	D	Â
Stock Option (right to purchase)	12/19/2012	12/20/2022	Common Stock	375	\$ 13.28	D	Â
Stock Option (right to purchase)	02/01/2014	02/02/2023	Common Stock	3,000	\$ 13.28	D	Â
Stock Option (right to purchase)	Â (1)	02/02/2023	Common Stock	18,754	\$ 13.28	D	Â
Stock Option (right to purchase)	04/25/2013	04/26/2023	Common Stock	375	\$ 14.74	D	Â
Stock Option (right to purchase)	05/14/2013	05/15/2023	Common Stock	375	\$ 14.74	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GROOPMAN JEROME C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940	Â X	Â	Â	Â

Signatures

/s/ Ajay Bansal, as attorney
in fact 07/24/2013

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option, representing a right to purchase a total of 18,754 shares of Common Stock, is immediately exercisable and vests over 4 years (1) from February 1, 2013, with 25% vesting on February 1, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

Â

Remarks:

Two of Two.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.